76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Fresenius SE & Co KGaA
Closed
SectorHealthcare
42.16 0.36
Overview
Share price change
24h
Min
41.96
Max
42.23
Income | 198M 471M |
|---|---|
Sales | 21M 5.7B |
P/E Sector Avg | 22.599 50.291 |
Dividend yield | 2.39 |
Profit margin | 8.335 |
Employees | 175,202 |
EBITDA | 225M 949M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +17.76% upside |
Dividend yield Sector Avg | 2.39% 2.40% |
|---|---|
Next Earnings | 6 Aug 2025 |
Market Cap | 2.7B 24B |
|---|---|
Previous open | 41.8 |
Previous close | 42.16 |
News Sentiment
By Acuity
35%
65%
121 / 380 Healthcare
Technical Score
By Trading Central
Confidence
Neutral Evidence
Fresenius SE & Co KGaA Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Fresenius SE & Co KGaA Forecast
Price Target
By TipRanks
17.76% upside
12 Months Forecast
Average 49.4 EUR 17.76%
High 52 EUR
Low 45 EUR
Based on 13 Wall Street analysts offering 12 month price targets forFresenius SE & Co KGaA - Dist in the last 3 months.
Sentiment
By Acuity
121 / 380 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Fresenius SE & Co KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
